$NPCE
Neuropace Inc

2023 Q4 Form 10-Q Financial Statement

#000152828723000041 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $18.01M $16.43M
YoY Change 40.84% 47.23%
Cost Of Revenue $4.467M $4.194M
YoY Change 12.07% 31.39%
Gross Profit $13.55M $12.23M
YoY Change 53.87% 53.58%
Gross Profit Margin 75.2% 74.47%
Selling, General & Admin $13.22M $13.39M
YoY Change -2.61% 6.65%
% of Gross Profit 97.59% 109.44%
Research & Development $5.377M $4.795M
YoY Change 5.66% -14.54%
% of Gross Profit 39.7% 39.2%
Depreciation & Amortization $40.00K $100.0K
YoY Change -25.93% 0.0%
% of Gross Profit 0.3% 0.82%
Operating Expenses $18.60M $18.18M
YoY Change -0.35% 0.1%
Operating Profit -$5.051M -$5.950M
YoY Change -48.77% -41.66%
Interest Expense -$1.414M $2.191M
YoY Change 23.93% 14.95%
% of Operating Profit
Other Income/Expense, Net $265.0K $115.0K
YoY Change -281.51% -211.65%
Pretax Income -$6.200M -$7.260M
YoY Change -44.37% -38.4%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.200M -$7.257M
YoY Change -44.37% -38.42%
Net Earnings / Revenue -34.42% -44.18%
Basic Earnings Per Share -$0.28
Diluted Earnings Per Share -$0.23 -$0.28
COMMON SHARES
Basic Shares Outstanding 26.28M shares 25.86M shares
Diluted Shares Outstanding 26.02M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.45M $61.30M
YoY Change -14.15% -28.23%
Cash & Equivalents $18.06M $9.717M
Short-Term Investments $48.40M $51.60M
Other Short-Term Assets $2.737M $1.600M
YoY Change -12.02% -36.03%
Inventory $11.21M $9.759M
Prepaid Expenses
Receivables $12.31M $11.28M
Other Receivables $0.00 $0.00
Total Short-Term Assets $92.72M $83.97M
YoY Change -5.11% -19.54%
LONG-TERM ASSETS
Property, Plant & Equipment $1.003M $949.0K
YoY Change -5.73% 6.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $15.00K
YoY Change -28.57% -28.57%
Total Long-Term Assets $14.93M $15.33M
YoY Change -8.91% -4.83%
TOTAL ASSETS
Total Short-Term Assets $92.72M $83.97M
Total Long-Term Assets $14.93M $15.33M
Total Assets $107.7M $99.30M
YoY Change -5.66% -17.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.332M $1.207M
YoY Change 8.62% 2.72%
Accrued Expenses $11.18M $10.04M
YoY Change 50.8% 32.93%
Deferred Revenue $1.100M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.23M $12.82M
YoY Change 47.86% 36.08%
LONG-TERM LIABILITIES
Long-Term Debt $56.95M $55.89M
YoY Change 7.64% 7.57%
Other Long-Term Liabilities $13.81M $14.20M
YoY Change -10.53% -9.52%
Total Long-Term Liabilities $56.95M $55.89M
YoY Change 7.64% 7.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.23M $12.82M
Total Long-Term Liabilities $56.95M $55.89M
Total Liabilities $87.00M $82.94M
YoY Change 9.67% 7.62%
SHAREHOLDERS EQUITY
Retained Earnings -$503.8M -$497.6M
YoY Change 6.99% 8.24%
Common Stock $28.00K $26.00K
YoY Change 12.0% 4.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.65M $16.36M
YoY Change
Total Liabilities & Shareholders Equity $107.7M $99.30M
YoY Change -5.66% -17.58%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$6.200M -$7.257M
YoY Change -44.37% -38.42%
Depreciation, Depletion And Amortization $40.00K $100.0K
YoY Change -25.93% 0.0%
Cash From Operating Activities -$3.341M -$2.300M
YoY Change -57.4% -67.03%
INVESTING ACTIVITIES
Capital Expenditures $32.00K $10.00K
YoY Change -68.63% -132.26%
Acquisitions
YoY Change
Other Investing Activities $3.500M $4.200M
YoY Change -61.11% -40.0%
Cash From Investing Activities $3.468M $4.190M
YoY Change -61.02% -39.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.214M -30.00K
YoY Change -6052.17% 275.0%
NET CHANGE
Cash From Operating Activities -3.341M -2.300M
Cash From Investing Activities 3.468M 4.190M
Cash From Financing Activities 8.214M -30.00K
Net Change In Cash 8.341M 1.860M
YoY Change 809.6% -13385.71%
FREE CASH FLOW
Cash From Operating Activities -$3.341M -$2.300M
Capital Expenditures $32.00K $10.00K
Free Cash Flow -$3.373M -$2.310M
YoY Change -57.55% -66.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12815000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10976000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14233000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15440000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
82937000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
79329000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26244935 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26244935 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
26000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
513946000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36998000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26017329 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26017329 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
34777000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10375000 usd
CY2023Q1 npce Oci Unrealized Loss Adjustment For Short Term Investment
OCIUnrealizedLossAdjustmentForShortTermInvestment
1108000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
55889000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52913000 usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
506713000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1108000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
2191000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1906000 usd
us-gaap Interest Expense
InterestExpense
6281000 usd
us-gaap Interest Expense
InterestExpense
5588000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
117000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1062000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7257000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11668000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26756000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25532415 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25532415 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24514820 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24514820 shares
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
146000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2125000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
27490000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9124000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
240000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
41000 usd
CY2023Q2 npce Adjustments To Additional Paid In Capital Change In Early Exercise Liability
AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
-1000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2655000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21226000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7257000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
35000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2421000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
73503000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11461000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-710000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2022Q1 npce Adjustments To Additional Paid In Capital Change In Early Exercise Liability
AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
-2000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1488000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
62823000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-469000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
679000 usd
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
47000 usd
CY2022Q2 npce Adjustments To Additional Paid In Capital Change In Early Exercise Liability
AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
-1000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2603000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
52902000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11785000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
117000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2182000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
43409000 usd
us-gaap Net Income Loss
NetIncomeLoss
-26756000 usd
us-gaap Net Income Loss
NetIncomeLoss
-35936000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7201000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6273000 usd
us-gaap Depreciation
Depreciation
132000 usd
us-gaap Depreciation
Depreciation
213000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
207000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
192000 usd
npce Increase Decrease In Non Cash Interest Expense
IncreaseDecreaseInNonCashInterestExpense
775000 usd
npce Increase Decrease In Non Cash Interest Expense
IncreaseDecreaseInNonCashInterestExpense
636000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1994000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1279000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1064000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2022000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-580000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-210000 usd
us-gaap Inventory Write Down
InventoryWriteDown
132000 usd
us-gaap Inventory Write Down
InventoryWriteDown
204000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3798000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
783000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
179000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
964000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1530000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
181000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-815000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-208000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2623000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
121000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1050000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2104000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16360000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29026000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
141000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
501000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
19700000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
15400000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19559000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14899000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
254000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
683000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
222000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
55000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
119000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-87000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
628000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3112000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13499000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9839000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5810000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9717000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5688000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
122000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
122000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9839000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5810000 usd
us-gaap Interest Paid Net
InterestPaidNet
3305000 usd
us-gaap Interest Paid Net
InterestPaidNet
3481000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10585000 usd
npce Increase Decrease In Accrued Liabilities Early Exercise Of Options
IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions
-1000 usd
npce Increase Decrease In Accrued Liabilities Early Exercise Of Options
IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions
-3000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29000000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
61300000 usd
npce Debt Instrument Covenant Minimum Annual Net Revenue
DebtInstrumentCovenantMinimumAnnualNetRevenue
45000000 usd
CY2023Q3 npce Debt Instrument Covenant Minimum Cash And Cash Equivalents Required After Completion Of Ipo
DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO
5000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three and nine months ended September 30, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of September 30, 2023 and December 31, 2022, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of comprehensive epilepsy centers, or CECs, and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
400000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26017329 shares
CY2023Q2 npce Research And Development Arrangement With Federal Government Approval For Funding Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2
3000000 usd
CY2023Q2 npce Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2
1500000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8303000 usd
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
51631000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
59934000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6075000 usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
70804000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
76879000 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0 usd
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71900000 usd
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
3179000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2818000 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1092000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1523000 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5488000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5371000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
9759000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9712000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9806000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9788000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8857000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8724000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
949000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1064000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
100000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
200000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8621000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5748000 usd
CY2023Q3 npce Accrued Inventory Liability Current
AccruedInventoryLiabilityCurrent
599000 usd
CY2022Q4 npce Accrued Inventory Liability Current
AccruedInventoryLiabilityCurrent
764000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
810000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
675000 usd
CY2023Q3 npce Accrued And Employee Related Liabilities Current
AccruedAndEmployeeRelatedLiabilitiesCurrent
10036000 usd
CY2022Q4 npce Accrued And Employee Related Liabilities Current
AccruedAndEmployeeRelatedLiabilitiesCurrent
7414000 usd
CY2022Q3 npce Operating Lease Renewal Term
OperatingLeaseRenewalTerm
P5Y
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24728701 shares
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
693000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2857000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2942000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3031000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3122000 usd
CY2023Q3 npce Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
8232000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
20877000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5072000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
15805000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1572000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14233000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
700000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
700000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2100000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2000000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
us-gaap Operating Lease Payments
OperatingLeasePayments
2100000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2100000 usd
CY2022Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
2400000 usd
CY2022Q3 npce Purchase Obligation Minimum Increase Percentage In Next Two Years
PurchaseObligationMinimumIncreasePercentageInNextTwoYears
0.10
CY2022Q3 us-gaap Longterm Purchase Commitment Period
LongtermPurchaseCommitmentPeriod
P12M
CY2023Q3 npce Indemnification Liability Officers And Directors
IndemnificationLiabilityOfficersAndDirectors
0 usd
CY2022Q4 npce Indemnification Liability Officers And Directors
IndemnificationLiabilityOfficersAndDirectors
0 usd
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2023Q1 npce Debt Instrument Principal Payment Number Of Installment
DebtInstrumentPrincipalPaymentNumberOfInstallment
1 installment
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7759322 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7076678 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3446583 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.61
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
695225 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
494849 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
662642 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2984317 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1874089 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2984317 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q3 npce Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
41907 shares
CY2022Q4 npce Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
78389 shares
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85
CY2021Q2 npce Employee Stock Purchase Plan Length Of Offering Period
EmployeeStockPurchasePlanLengthOfOfferingPeriod
P6M
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7257000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11785000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26756000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35936000 usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26017329 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2421000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2182000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7201000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6273000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2421000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2182000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7201000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6273000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
17800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24728701 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25532415 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25532415 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24514820 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5664776 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5567943 shares

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
npce-20230930_lab.xml Edgar Link unprocessable
npce-20230930_cal.xml Edgar Link unprocessable
npce-20230930_def.xml Edgar Link unprocessable
0001528287-23-000041-index-headers.html Edgar Link pending
0001528287-23-000041-index.html Edgar Link pending
0001528287-23-000041.txt Edgar Link pending
0001528287-23-000041-xbrl.zip Edgar Link pending
exhibit311-certificationsq.htm Edgar Link pending
exhibit312certificationsq3.htm Edgar Link pending
exhibit321certificationsq3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
npce-20230930.htm Edgar Link pending
npce-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
npce-20230930_pre.xml Edgar Link unprocessable
npce-20230930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending